Getting predictive technologies to patients, with Concr

Europe for life sciences and for patients, with BeOne Medicines

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

Delivering prevention at scale, PA Consulting’s James Davis

Decentralisation by design: bringing the trial closer without adding complexity

Understanding Operation Trialblazer, with Dr Harpreet Singh

Technology solutions for smarter clinical trials: Inventus

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche

Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran

Patient population first: the strategy behind country decisions

CAMP4 on a new class of ASO in gene under expression

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, with Tony Jarkowski

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

ASCO 2026: Pluvicto shows consistency, with Dr Fred Saad

ASCO 2026: All about DNA damage response, with Debiopharm's Luke Piggot

ASCO 2026: Time is tissue: A promising treatment in AL amyloidosis, with Dr Hans Lee

Purespring on nephrology & gene therapy in kidney disease

The evolving role of GLP-1s in oncology research, with Dr Jess Paulus

Parexel: Flawless execution, policy shifts & patient-centric design

ASCO 2026: Three ADC approvals in five days, with Ken Keller and John Tsai

ASCO 2026: Can a blood test spot cancer early? with Dr Peter Sasieni

ASCO 2026: A potential functional cure in endometrial cancer, with Eric Richards

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

ASCO 2026: Could ADCs finally replace chemotherapy? With AbbVie’s Pedro Valencia

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

ASCO 2026: Can your microbiome effect your response to cancer treatment? with Dr Rahul Winayak

ASCO 2026: Quality of life, not just quantity, with Dr Harold Keer

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa Bitetti and PK Morrow

Biosimilars & patient access independent of geographies or socioeconomics, with Rebecca Guntern

ASCO 2026: First to first line in HER-2 NSCLC, with Itziar Canamasas

ASCO 2026: Chinese firms take a front seat in oncology, with Li Mao and Giovanni Selvaggi

ASCO 2026: Precision medicine takes a village, with Carolyn Sousa and Henar Hevia

Towards a healthier world: Momentum in UK health system transformation, with Lee-Ann Farrell

ASCO: Three strong Pfizer Phase 3s, with Johanna Bendell

ASCO26: Agentic AI supercharging genome sequencing for early cancer detection, with David Spetzler

IQVIA on reducing complexity and workload for clinical trial sites

Trustworthy and novel AI in clinical trial planning, with Kris Kaneta

Rethinking clinical research: The case for human challenge trials

The cardio-renal-metabolic space and obesity as a chronic disease, with Ramy Younes

From data to deployment: Navigating AI adoption in pharma with Veeva

On the power of T-cells, with Cedrik Britten

Why everyone should care about longevity, with Boyang Wang

A philosophical look at market turn in the Age of AI, with John Holodnak

Providing patient access to new therapies, with Dean Erhardt

LSX2026: Endogenous tissue restoration in vascular disease – Insights from Paulo Neves

Pushing through barriers to commercial launch success, with Amanjeet Singh Saluja

Every drug is a story, with Thomas Goetz

LSX2026: Non-opioid pain relief and pharma positivity, with Mike Cooke

LSX2026: Addressing adult eye cancer, with Roi Raz

Making direct-to-patient work, with Matt Wadyka

Looking to gene therapy for ocular diseases, with Lance Baldo

Biotech is back, with Craig Ackerman

LSX2026: On a therapeutic vision for ocular disease, with Alexander Gebauer

LSX2026: On promise and patience, with Hans Schambye

Creating what nature has not from AI and computational molecular biophysics with Kashif Sadiq

BIO-Europe Spring 2026: In conversation with Marjorie Sidhoum

Hernexeos and what’s next, with Vicky Brown

On collaboration, computational chemistry, and cutting-edge AI – with Olga Nissan

Using patient data to fill in GLP-1 blind spots, with Phil Johnson

BIO-Europe Spring 2026: In conversation with Robert Jacks